In:
Journal of the American Heart Association, Ovid Technologies (Wolters Kluwer Health), Vol. 6, No. 2 ( 2017-02-02)
Abstract:
Elevated high‐sensitivity C‐reactive protein (hs CRP ) has been associated with increased risks of adverse outcomes of various cardiovascular diseases. The relationship between hs CRP and the prognosis of hypertrophic cardiomyopathy remains to be evaluated. Methods and Results The study used an observational cohort methodology. A total of 490 patients were enrolled in the Fuwai Hospital from 2001 to 2011 and were followed for 3.7±2.0 years. According to the risk category of hs CRP , subjects in the high hs CRP group ( 〉 3.0 mg/L) had a higher risk of developing adverse events than the low hs CRP group ( 〈 1.0 mg/L): cardiovascular death (adjusted hazard ratios[ HR ] 5.41, 95% CI 1.96–14.93, P =0.001), all‐cause mortality (adjusted HR 4.78, 95% CI 1.99–11.47, P 〈 0.001), sudden cardiac death (adjusted HR 11.29, 95% CI 1.38–92.20, P =0.024), and heart failure–related death (adjusted HR 4.38, 95% CI 1.15–16.60, P =0.030). Similarly, the continuous variable of hs CRP was also an independent predictor for adverse outcomes: cardiovascular death (adjusted HR 1.15, 95% CI 1.06–1.25, P =0.001), all‐cause mortality (adjusted HR 1.17, 95% CI 1.09–1.26, P 〈 0.001), sudden cardiac death (adjusted HR 1.20, 95% CI 1.06–1.36, P =0.003), and heart failure–related death (adjusted HR 1.15, 95% CI 1.02–1.30, P =0.020). Conclusions Our results indicate that elevated plasma hs CRP is associated with increased risk for adverse outcomes in patients with hypertrophic cardiomyopathy.
Type of Medium:
Online Resource
ISSN:
2047-9980
DOI:
10.1161/JAHA.116.004529
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2017
detail.hit.zdb_id:
2653953-6
Permalink